• The Journal of Korean Obstetrics and Gynecology
• /
• v.25 no.1
• /
• pp.11-19
• /
• 2012

Purpose: The purpose of this study is to evaluate the synergic efficacy of oriental herb medicine for osteoporosis patients by examining whether there is any change in BMD. Osteoporosis patients are classified into a group having taken Fosamax and the other group having taken Fasamax and Samgieumgamibang in this study. Methods: Mean BMD and T-score are measured in all patients before and 3 months after treatment. Results: 1. The group having taken Fosamax showed no statistically significant mean BMD change before and after treatment. 2. The group having taken Fosamax showed no statistically significant T-score change before and after treatment. 3. The group having taken both Fosamax and Samgieumgamibang showed increase in mean BMD, which does not bear statistically significant change. 4. The group having taken both Fosamax and Samgieumgamibang showed statistically significant T-score change before and after treatment(p<0.05). Conclusions: After treatment, BMD in patients having taken Fosamx did not change significantly, but in patients having taken both Fosamax and Samgieumgamibang increased, which proves the efficacy of oriental herb medicine for osteoporosis patients.

• Journal of Pharmaceutical Investigation
• /
• v.36 no.2
• /
• pp.137-142
• /
• 2006

A bioequivalence of Daewoong $Alendronate^{TM}$ (Daewoong Pharmaceutical Co., Ltd., Korea) and $Fosamax^{TM}$ tablets (MSD Korea) was evaluated according to the guideline of Korea Food and Drug Administration (KFDA). A single 70 mg dose of sodium alendronate of each medicine was administered orally to 56 healthy male volunteers. This study was performed in a $2\;{\time}\;2$ crossover design. Concentrations of alendronate in the urine were monitored by a high-performance liquid chromatography (HPLC). $A_{et}$ (cumulative urinary excreted amount from time 0 to last sampling interval) was calculated by the accumulation of the urinary excreted alendronate. $U_{max}$ (maximum urinary excretion rate) and $T_{max}$ (time to reach $U_{max}$) were compiled from the urinary excretion rate - time data. Analysis of variance was performed using logarithmically transformed $A_{et}$ and $U_{max}$. No significant sequence effect was found for all of the bioavailability parameters. The 90% confidence intervals of the $A_{et}$ and $U_{max}$ for Daewoong $Alendronate^{TM}/Fosamax^{TM}$ were 0.89-1.12 and 0.82-1.02, respectively. This study demonstrated the bioequivalence of Daewoong $Alendronate^{TM}$ and $Fosamax^{TM}$ with respect to the rate and extent of absorption.

• Maxillofacial Plastic and Reconstructive Surgery
• /
• v.36 no.2
• /
• pp.57-61
• /
• 2014

Bisphosphonate is used widely for osteoporosis treatment, but a rising concern is the risk of osteonecrosis after long-term bisphosphonate use. Such cases are increasing, suggesting a need for research to prevent and treat bisphosphonate-related osteonecrosis of jaws. A 63-year-old female took bisphosphonate (Fosamax$^{(R)}$) for four years for treatment of osteoporosis and stopped medication two months ago because of unhealed wound. She was treated with marginal mandibulectomy maintaining the inferior border, and a metal plate was placed to prevent mandible fracture. Four months after the mandibulectomy, mandible reconstruction surgery using iliac bone and allograft was done. Six months after reconstruction, implant placement and treatment with an overdenture was done without complications. This study presents a case with a successful result.